PRESS RELEASE
from Fresenius SE & Co. KGaA (isin : DE0005785604)
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Miscellaneous
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation
09-Feb-2023 / 16:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft).
The Else Kröner-Fresenius-Stiftung which holds all shares in the Issuer’s general partner has informed the Issuer that it has taken note with approval of the Issuer’s plans to deconsolidate FMC by way of a change of the legal form into a stock corporation. The Issuer wishes to point out, however, that the analysis is not yet completed and the required decisions by the competent bodies within the group are still outstanding.
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., February 9, 2023
Contact:Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
End of Note
The Else Kröner-Fresenius-Stiftung which holds all shares in the Issuer’s general partner has informed the Issuer that it has taken note with approval of the Issuer’s plans to deconsolidate FMC by way of a change of the legal form into a stock corporation. The Issuer wishes to point out, however, that the analysis is not yet completed and the required decisions by the competent bodies within the group are still outstanding.
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., February 9, 2023
Contact:Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
End of Note
09-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Fresenius SE & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg v.d.H. | |
| Germany | |
| Phone: | +49 (0)6172 608-2485 |
| Fax: | +49 (0)6172 608-2488 |
| E-mail: | ir-fre@fresenius.com |
| Internet: | www.fresenius.com |
| ISIN: | DE0005785604 |
| WKN: | 578560 |
| Indices: | DAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 1556469 |
| End of Announcement | EQS News Service |
1556469 09-Feb-2023 CET/CEST